Live
FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonistsBioWorldIteos Belgium discloses new PTPN1/2 inhibitorsBioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIVBioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patentLabiotechNew names, new narratives: Why biotechs decide to rebrandPharmaVoiceThe biotech market is rebounding. So where are the executive jobs?FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A options
Bio-Rad Apr 30, 2026

Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus

Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus

Original
Body unavailable. Use the original source.